Janssen’s Esketamine Needs Better Defined REMS, US FDA Panel Says

 
• By Sue Sutter

Advisory committee overwhelmingly endorses approval for patients with treatment-resistant depression but says proposed Risk Evaluation and Mitigation Strategy needs refinement, including clarifying the types of facilities where the drug will be administered.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers